**Chapter 7**

[256] Shi L. Anti-neutrophil cytoplasmic

*The Recent Topics in Genetic Polymorphisms*

Rheumatology Reports. 2015;**17**(2):6. DOI: 10.1007/s11926-014-0480-1

[264] Stanford SM, Bottini N. PTPN22: The archetypal non-HLA autoimmunity gene. Nature Reviews Rheumatology. 2014;**10**(10):602-611. DOI: 10.1038/

[265] Serrano A, Márquez A, Mackie SL, et al. Identification of the PTPN22 functional variant R620W as

susceptibility genetic factor for giant cell arteritis. Annals of the Rheumatic Diseases. 2013;**72**(11):1882-1886. DOI: 10.1136/annrheumdis-2013-203641

[266] Carmona FD, Mackie SL, Martín JE, et al. A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility. American Journal

of Human Genetics. 2015;**96**(4): 565-580. DOI: 10.1016/j.ajhg.2015.

RMD Open. 2016;**2**(1):e000246. Published Apr 7, 2016. DOI: 10.1136/

rmdopen-2016-000246

10.1159/000321239

Addison's disease. Endocrine

[270] Roycroft M, Fichna M,

allele of the lymphoid tyrosine phosphatase (PTPN22) gene

**70**(3):358-362. DOI: 10.1111/ j.1365-2265.2008.03380.x

McDonald D, et al. The tryptophan 620

predisposes to autoimmune Addison's disease. Clinical Endocrinology. 2009;

[267] Lester S, Hewitt AW, Ruediger CD, et al. PTPN22 R620W minor allele is a genetic risk factor for giant cell arteritis.

[268] Betterle C, Morlin L. Autoimmune

Development. 2011;**20**:161-172. DOI:

[269] Skinningsrud B, Husebye ES, Gervin K, et al. Mutation screening of PTPN22: Association of the 1858T-allele with Addison's disease. European Journal of Human Genetics. 2008;**16**(8): 977-982. DOI: 10.1038/ejhg.2008.33

02.009

nrrheum.2014.109

Prevalence, treatment, and outcomes. Rheumatology International. 2017; **37**(11):1779-1788. DOI: 10.1007/

[257] Willcocks LC, Lyons PA, Rees AJ, Smith KG. The contribution of genetic

[258] Alberici F, Martorana D, Vaglio A. Genetic aspects of anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrology, Dialysis, Transplantation. 2015;**30**(Suppl 1):i37-

[259] Jagiello P, Aries P, Arning L, et al. The PTPN22 620W allele is a risk factor for Wegener's granulomatosis. Arthritis

[260] Carr EJ, Niederer HA, Williams J, et al. Confirmation of the genetic association of CTLA4 and PTPN22 with ANCA-associated vasculitis. BMC Medical Genetics. 2009;**10**:121. Published Dec 1, 2009. DOI: 10.1186/

[262] Cao Y, Liu K, Tian Z, et al. PTPN22 R620W polymorphism and ANCA disease risk in white populations: A metaanalysis. The Journal of Rheumatology. 2015;**42**(2):292-299. DOI: 10.3899/jrheum.131430

[263] González-Gay MA, Pina T. Giant cell arteritis and polymyalgia rheumatica: An update. Current

**122**

antibody-associated vasculitis:

variation and infection to the pathogenesis of ANCA-associated systemic vasculitis. Arthritis Research & Therapy. 2010;**12**(1):202. DOI: 10.1186/

i45. DOI: 10.1093/ndt/gfu386

and Rheumatism. 2005;**52**(12): 4039-4043. DOI: 10.1002/art.21487

[261] Martorana D, Maritati F, Malerba G, et al. PTPN22 R620W polymorphism in the ANCA-associated vasculitides. Rheumatology (Oxford, England). 2012;**51**(5):805-812. DOI: 10.1093/rheumatology/ker446

1471-2350-10-121

s00296-017-3818-y

ar2928
